Neuen BL, Ohkuma T, Neal B, et al. - In this post-hoc analysis of data from the CANagliflozin cardioVascular Assessment Study Program, researchers evaluated the impacts of canagliflozin on renal, cardiovascular, and safety results by baseline albuminuria among 2,266 (22.3%) patients with T2D and high cardiovascular risk who were randomized to canagliflozin or placebo, and had moderately raised albuminuria (urinary albumin/creatinine ratio [UACR] 30–300 mg/g) and 760 (7.5%) with severely raised albuminuria (UACR > 300 mg/g) at baseline. Albuminuria reduction was induced by canagliflozin with greater proportional decreases in those with moderately and severely elevated albuminuria. Findings revealed mostly consistent proportional influences of canagliflozin on renal and cardiovascular outcomes across patients with different levels of albuminuria, however, those with severely increased albuminuria demonstrated the greatest absolute benefits.